The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Clinical management of herpes simplex virus infections: past, present, and future
Open accessAbstract
Infection with herpes simplex virus (HSV) types 1 and 2 is ubiquitous in the human population. Most commonly, virus replication is limited to the epithelia and establishes latency in enervating sensory neurons, reactivating periodically to produce localized recurrent lesions. However, these viruses can also cause severe disease such as recurrent keratitis leading potentially to blindness, as well as encephalitis, and systemic disease in neonates and immunocompromised patients. Although antiviral therapy has allowed continual and substantial improvement in the management of both primary and recurrent infections, resistance to currently available drugs and long-term toxicity pose a current and future threat that should be addressed through the development of new antiviral compounds directed against new targets. The development of several promising HSV vaccines has been terminated recently because of modest or controversial therapeutic effects in humans. Nevertheless, several exciting vaccine candidates remain in the pipeline and are effective in animal models; these must also be tested in humans for sufficient therapeutic effects to warrant continued development. Approaches using compounds that modulate the chromatin state of the viral genome to suppress infection and reactivation or induce enhanced antiviral immunity have potential. In addition, technologies such as CRISPR/Cas9 have the potential to edit latent viral DNA in sensory neurons, potentially curing the neuron and patient of latent infection. It is hoped that development on all three fronts—antivirals, vaccines, and gene editing—will lead to substantially less HSV morbidity in the future.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Vidarabine versus Acyclovir Therapy in Herpes Simplex Encephalitis
Whitley, R. J., Alford, C. A., Hirsch, M. S., Schooley, R. T., Luby, J. P., Aoki, F. Y., Hanley, D., Nahmias, A. J., Soong, S.-J., & The NIAID Collaborative Antiviral Study Group* (1986) · New England Journal of Medicine · doi:10.1056/nejm198601163140303 · Cited by 896
Self-citationManagement of Herpes simplex virus epithelial keratitis
Roozbahani, M., & Hammersmith, K. M. (2018) · Current Opinion in Ophthalmology · doi:10.1097/icu.0000000000000483 · Cited by 47
Cited by
Herpes simplex virus: global infection prevalence and incidence estimates, 2016
James, C., Harfouche, M., Welton, N. J., Turner, K. M., Abu-Raddad, L. J., Gottlieb, S. L., & Looker, K. J. (2020) · Bulletin of the World Health Organization · doi:10.2471/blt.19.237149 · Cited by 791
Viral Infections Confined to Tattoos—A Narrative Review
Tampa, M., Mitran, M. I., Mitran, C. I., Matei, C., Amuzescu, A., Buzatu, A. A., & Georgescu, S. R. (2022) · Medicina · doi:10.3390/medicina58030342 · Cited by 12
Preparation of antibodies against TXR1 and construction of a new DNA tumor vaccine
Sun, Y., Zhang, X., Yang, S., Hu, C., Pan, J., Liu, T., Ding, J., Han, C., Huang, Y., & Yang, K. (2022) · International Immunopharmacology · doi:10.1016/j.intimp.2021.108505 · Cited by 3
Metadata
- Authors
- Whitley, R., & Baines, J.
- Venue
- F1000Research
- Publisher
- F1000 Research Ltd
- Published
- 2018-10-31
- Volume
- 7
- Pages
- 1726
- ISSN
- 2046-1402 (ISSN-L)
- OpenAlex
- W2899477426
- Cited by
- 187
- References
- 2
- FWCI
- 10.74
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Clinical management of herpes simplex virus infections: past, present, and future. https://app.cochat.ai/papers/10.12688/f1000research.16157.1
- The paper
- Whitley, R., & Baines, J. (2018). Clinical management of herpes simplex virus infections: past, present, and future. F1000Research. https://doi.org/10.12688/f1000research.16157.1
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.